end stage renal disease
Conditions
Interventions
None listed
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients treated with chronic low-flux hemodialysis (longer than 3 months) Older than 18 years Ability to give informed consent
Exclusion criteria
Exclusion criteria: Acute renal failure Inability to give informed consent Prior treatment with on-line hemodiafiltration within the last 6 months Severe intercurrent disease Dementia Life expectancy less than 6 months history of hypersensitivity reaction to polysulphone or cellulose triacetate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome parameter is the pre-dialytic plasma level of Beta-2 microglobulin. | — |
Secondary
| Measure | Time frame |
|---|---|
| Plasma levels and clearance of other larger molecular weight toxins (such as complement factor D, carboxmethyllysine, homocysteine). Albumin loss during treatment and the effect on immune status [FACS] will also be studied. | — |
Countries
Netherlands
Outcome results
None listed